This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (eHealth) (671) Mobile Health (mhealth) (3481) Depression and Mood Disorders; Suicide Prevention (1701) Prescribable Digital Interventions (Digital Therapeutics) (45) Engagement with and Adherence to Digital Health Interventions, Law of Attrition (643) AI-Powered Therapy Bots and Virtual Companions in Digital Mental Health (29)

Published on in Vol 14 (2025)

This is a member publication of University of Washington

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/81293, first published .
Effectiveness, Engagement, and Safety of a Digital Therapeutic (CT-155/BI 3972080) for Treating Negative Symptoms in People With Schizophrenia: Protocol for the Phase 3 CONVOKE Randomized Controlled Trial

Effectiveness, Engagement, and Safety of a Digital Therapeutic (CT-155/BI 3972080) for Treating Negative Symptoms in People With Schizophrenia: Protocol for the Phase 3 CONVOKE Randomized Controlled Trial

Effectiveness, Engagement, and Safety of a Digital Therapeutic (CT-155/BI 3972080) for Treating Negative Symptoms in People With Schizophrenia: Protocol for the Phase 3 CONVOKE Randomized Controlled Trial

Authors of this article:

Shaheen E Lakhan1 Author Orcid Image ;   Cornelia Dorner-Ciossek2 Author Orcid Image ;   Olya Besedina1 Author Orcid Image ;   Faith Dickerson3 Author Orcid Image ;   Claudia Hastedt2 Author Orcid Image ;   Ridwana Isla4 Author Orcid Image ;   René S Kahn5 Author Orcid Image ;   Jean-Pierre Lindenmayer6 Author Orcid Image ;   Ruchi Mehta1 Author Orcid Image ;   Cassandra Snipes1 Author Orcid Image ;   Austin Speier1 Author Orcid Image ;   Wenbo Tang4 Author Orcid Image ;   Bailey Willis1 Author Orcid Image ;   Jamie Winderbaum Fernandez7 Author Orcid Image ;   Christoph von der Goltz2 Author Orcid Image ;   Abhishek Pratap4 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics

Shaheen E Lakhan   1 , PhD ;   Cornelia Dorner-Ciossek   2 , PhD ;   Olya Besedina   1 , MS ;   Faith Dickerson   3 , MPH, PhD ;   Claudia Hastedt   2 , PhD ;   Ridwana Isla   4 , PMP ;   René S Kahn   5 , MD, PhD ;   Jean-Pierre Lindenmayer   6 , MD ;   Ruchi Mehta   1 , MSc ;   Cassandra Snipes   1 , PhD ;   Austin Speier   1 , BA ;   Wenbo Tang   4 , PhD ;   Bailey Willis   1 , MSc ;   Jamie Winderbaum Fernandez   7 , MD ;   Christoph von der Goltz   2 , MD ;   Abhishek Pratap   4 , PhD

1 Click Therapeutics Inc, New York, NY, United States

2 Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany

3 Sheppard Pratt Health System, Towson, MD, United States

4 Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, United States

5 Icahn School of Medicine at Mount Sinai, New York, NY, United States

6 Department of Psychiatry, New York University, New York, NY, United States

7 IPTB Clinical Research, Tampa, FL, United States

Corresponding Author: